Abnormalities in airway mucus lead to chronic disorders in the pulmonary system such as asthma, fibrosis and chronic obstructive pulmonary disease (COPD). Among these, COPD is more prominent worldwide. Various conventional approaches are available in the market for the treatment of COPD, but the delivery of drugs to the target site remains a challenge with conventional approaches. Nanocarrier-based approaches are considered the best due to their sustained release properties to the target site, smaller size, high surface-to-volume ratio, patient compliance, overcoming airway defenses and improved pharmacotherapy. This article provides updated information about the treatment of COPD along with nanocarrier-based approaches as well as the potential of gene therapy and stem cell therapy to combat the COPD.

Keywords:

References

1. Quaderi SA, Hurst JR. The unmet global burden of COPD. Glob. Health Epidemiol. Genomics 3, e4 (2018).
Medline CASGoogle Scholar
2. Repine JE, Bast A, Lankhorst I. The oxidative stress study group. Oxidative stress in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 156(2), 341–357 (1997).
Medline CASGoogle Scholar
3. Rahman I. The role of oxidative stress in the pathogenesis of COPD: implications for therapy. Treat. Respir. Med. 4(3), 175–200 (2005).
MedlineGoogle Scholar
4. Yanai M, Sekizawa K, Ohrui T, Sasaki H, Takishima T. Site of airway obstruction in pulmonary disease: direct measurement of intrabronchial pressure. J. Appl. Physiol. 72(3), 1016–1023 (1992).
Medline CASGoogle Scholar
5. Carnevali S, Petruzzelli S, Longoni B et al. Cigarette smoke extract induces oxidative stress and apoptosis in human lung fibroblasts. Am. J. Physiol. Lung Cell. Mol. Physiol. 284(6), L955–963 (2003).
Medline CASGoogle Scholar
6. Togo S, Holz O, Liu X et al. Lung fibroblast repair functions in patients with chronic obstructive pulmonary disease are altered by multiple mechanisms. Am. J. Respir. Crit. Care Med. 178(3), 248–260 (2008).
Medline CASGoogle Scholar
7. Rodrigues SDO, da Cunha CMC, Soares GMV, Silva PL, Silva AR, Gonçalves-de-Albuquerque CF. Mechanisms, pathophysiology and currently proposed treatments of chronic obstructive pulmonary disease. Pharmaceuticals 14(10), 979 (2021).
Medline CASGoogle Scholar
8. Thimmulappa RK, Chattopadhyay I, Rajasekaran S. Oxidative stress mechanisms in the pathogenesis of environmental lung diseases. Oxidative Stress Lung Dis. 2, 103–137 (2019).
Google Scholar
9. Walters EH, Shukla SD, Mahmood MQ, Ward C. Fully integrating pathophysiological insights in COPD: an updated working disease model to broaden therapeutic vision. Eur. Respir. Rev. 30(160), 200364(2021). https://err.ersjournals.com/content/30/160/200364
MedlineGoogle Scholar
10. Hogg JC, Paré PD, Hackett T-L. The contribution of small airway obstruction to the pathogenesis of chronic obstructive pulmonary disease. Physiol. Rev. 97(2), 529–552 (2017).
MedlineGoogle Scholar
11. Rao W, Wang S, Duleba M et al. Regenerative metaplastic clones in COPD lung drive inflammation and fibrosis. Cell 181(4), 848–864.e18 (2020).
Medline CASGoogle Scholar
12. Barnes PJ, Baker J, Donnelly LE. Cellular senescence as a mechanism and target in chronic lung diseases. Am. J. Respir. Crit. Care Med. 200(5), 556–564 (2019).
Medline CASGoogle Scholar
13. Baker JR, Vuppusetty C, Colley T et al. MicroRNA-570 is a novel regulator of cellular senescence and inflammaging. FASEB J. 33(2), 1605–1616 (2019).
Medline CASGoogle Scholar
14. Herbig U, Jobling WA, Chen BPC, Chen DJ, Sedivy JM. Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21CIP1, but not p16INK4a. Mol. Cell 14(4), 501–513 (2004).
Medline CASGoogle Scholar
15. Kuźnar-Kamińska B, Mikuła-Pietrasik J, Witucka A et al. Serum from patients with chronic obstructive pulmonary disease induces senescence-related phenotype in bronchial epithelial cells. Sci. Rep. 8(1), 12940 (2018).
MedlineGoogle Scholar
16. Diaz AA, Maselli DJ, Rahaghi F et al. Pulmonary vascular pruning in smokers with bronchiectasis. ERJ Open Res. 4(4), 00044–02018 (2018).
MedlineGoogle Scholar
17. Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu. Rev. Pathol. Mech. Dis. 4(1), 435–459 (2009).
CASGoogle Scholar
18. Boucher RC. Muco-obstructive lung diseases. N. Engl. J. Med. 380(20), 1941–1953 (2019).
Medline CASGoogle Scholar
19. Koo H-K, Vasilescu DM, Booth S et al. Small airways disease in mild and moderate chronic obstructive pulmonary disease: a cross-sectional study. Lancet Respir. Med. 6(8), 591–602 (2018).
MedlineGoogle Scholar
20. Hattesohl ADM, Jörres RA, Dressel H et al. Discrimination between COPD patients with and without alpha 1-antitrypsin deficiency using an electronic nose: eNose discrimination of COPD and AATD. Respirology 16(8), 1258–1264 (2011).
MedlineGoogle Scholar
21. Alp G, Aydogan N. Lipid-based mucus penetrating nanoparticles and their biophysical interactions with pulmonary mucus layer. Eur. J. Pharm. Biopharm. 149, 45–57 (2020).
Medline CASGoogle Scholar
22. Antus B. Pharmacotherapy of chronic obstructive pulmonary disease: a clinical review. ISRN Pulmonol. 2013, 1–11 (2013).
Google Scholar
23. Hsu E, Bajaj T. Beta 2 agonists [Internet]. In: StatPearls, StatPearls Publishing, FL, USA (2021).
Google Scholar
24. Saberi F, O'Donnell DE. The role of tiotropium bromide, a long-acting anticholinergic bronchodilator, in the management of COPD. Treat. Respir. Med. 4(4), 275–281 (2005).
Medline CASGoogle Scholar
25. Barr RG, Rowe BH, Camargo CA. Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials. BMJ 327(7416), 643 (2003).
Medline CASGoogle Scholar
26. Falk JA, Minai OA, Mosenifar Z. Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 5(4), 506–512 (2008).
Medline CASGoogle Scholar
27. Chong J, Leung B, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2017(9), CD002309 (2017).
Google Scholar
28. Rogers DF. Mucoactive drugs for asthma and COPD: any place in therapy? Expert Opin. Investig. Drugs 11(1), 15–35 (2002).
Medline CASGoogle Scholar
29. Qiu S, Zhong X. Macrolides: a promising pharmacologic therapy for chronic obstructive pulmonary disease. Ther. Adv. Respir. Dis. 11(3), 147–155 (2017).
Medline CASGoogle Scholar
30. Fischer BM, Voynow JA, Ghio AJ. COPD: balancing oxidants and antioxidants. Int. J. Chron. Obstruct. Pulmon. Dis. 10, 261–276 (2015).
Medline CASGoogle Scholar
31. Yousuf A, Brightling CE. Biologic drugs: a new target therapy in COPD? COPD. 15(2), 99–107 (2018).
MedlineGoogle Scholar
32. Raju SV, Solomon GM, Dransfield MT, Rowe SM. Acquired CFTR dysfunction in chronic bronchitis and other diseases of mucus clearance. Clin. Chest Med. 37(1), 147–158 (2016).
MedlineGoogle Scholar
33. Passi M, Shahid S, Chockalingam S, Sundar IK, Packirisamy G. Conventional and nanotechnology based approaches to combat chronic obstructive pulmonary disease: implications for chronic airway diseases. Int. J. Nanomed. 15, 3803–3826 (2020).
Medline CASGoogle Scholar
34. Chen G, Roy I, Yang C, Prasad PN. Nanochemistry and nanomedicine for nanoparticle-based diagnostics and therapy. Chem. Rev. 116(5), 2826–2885 (2016).
Medline CASGoogle Scholar
35. Matsuo Y, Ishihara T, Ishizaki J, Miyamoto K, Higaki M, Yamashita N. Effect of betamethasone phosphate loaded polymeric nanoparticles on a murine asthma model. Cell. Immunol. 260(1), 33–38 (2009).
Medline CASGoogle Scholar
36. Montuschi P, Malerba M, Macis G, Mores N, Santini G. Triple inhaled therapy for chronic obstructive pulmonary disease. Drug Discov. Today 21(11), 1820–1827 (2016).
Medline CASGoogle Scholar
37. Jain KK. Current status and future prospects of drug delivery systems. Methods Mol. Biol. Clifton NJ. 1141, 1–56 (2014).
Medline CASGoogle Scholar
38. Virmani T, Virmani R, Singh SS, Gupta J. Nanoparticle formulation-a new approach to enhance dissolution & oral bioavailability of poorly soluble drugs. Int. J. Multidiscip. Sci. 1, 1–3 (2018).
Google Scholar
39. Alexescu TG, Tarmure S, Negrean V et al. Nanoparticles in the treatment of chronic lung diseases. J. Mind Med. Sci. 6(2), 224–231 (2019).
Google Scholar
40. Ratemi E, Sultana Shaik A, Al Faraj A, Halwani R. Alternative approaches for the treatment of airway diseases: focus on nanoparticle medicine. Clin. Exp. Allergy 46(8), 1033–1042 (2016).
Medline CASGoogle Scholar
41. Mahapatro A, Singh DK. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J. Nanobiotechnol. 9(1), 55 (2011).
Medline CASGoogle Scholar
42. Yavuz B, Pehlivan SB, Vural İ, Ünlü N. In vitro/in vivo evaluation of dexamethasone–PAMAM dendrimer complexes for retinal drug delivery. J. Pharm. Sci. 104(11), 3814–3823 (2015).
Medline CASGoogle Scholar
43. Jaiswal M, Dudhe R, Sharma PK. Nanoemulsion: an advanced mode of drug delivery system. 3 Biotech. 5(2), 123–127 (2015).
MedlineGoogle Scholar
44. Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages. Res. Pharm. Sci. 13(4), 288–303 (2018).
MedlineGoogle Scholar
45. Yokoyama M. Polymeric micelles as drug carriers: their lights and shadows. J. Drug Target 22(7), 576–583 (2014).
Medline CASGoogle Scholar
46. Kazi KM, Mandal AS, Biswas N et al. Niosome: a future of targeted drug delivery systems. J. Adv. Pharm. Technol. Res. 1(4), 374–380 (2010).
MedlineGoogle Scholar
47. Smola M, Vandamme T, Sokolowski A. Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases. Int. J. Nanomed. 3(1), 1–19 (2008).
CASGoogle Scholar
48. Osman N, Kaneko K, Carini V, Saleem I. Carriers for the targeted delivery of aerosolized macromolecules for pulmonary pathologies. Expert Opin. Drug Deliv. 15(8), 821–834 (2018).
Medline CASGoogle Scholar
49. Lee Y, Thompson DH. Stimuli-responsive liposomes for drug delivery. WIREs Nanomed. Nanobiotechnol. 9(5), (2017). https://onlinelibrary.wiley.com/doi/10.1002/wnan.1450
Google Scholar
50. Lee JH, Yeo Y. Controlled drug release from pharmaceutical nanocarriers. Chem. Eng. Sci. 125, 75–84 (2015).
Medline CASGoogle Scholar
51. Pinheiro M, Lúcio M, Lima JLFC, Reis S. Liposomes as drug delivery systems for the treatment of TB. Nanomed. 6(8), 1413–1428 (2011).
CASGoogle Scholar
52. Allen TM. Liposomal drug formulations. Rationale for development and what we can expect for the future. Drugs 56(5), 747–756 (1998).
Medline CASGoogle Scholar
53. Konduri KS, Nandedkar S, Rickaby DA, Düzgüneş N, Gangadharam PRJ. The use of sterically stabilized liposomes to treat asthma. Methods Enzymol. 391, 413–427 (2005).
Medline CASGoogle Scholar
54. Karn PR, Vanić Z, Pepić I, Skalko-Basnet N. Mucoadhesive liposomal delivery systems: the choice of coating material. Drug Dev. Ind. Pharm. 37(4), 482–488 (2011).
Medline CASGoogle Scholar
55. Adel IM, ElMeligy MF, Abdelrahim MEA et al. Design and characterization of spray-dried proliposomes for the pulmonary delivery of curcumin. Int. J. Nanomed. 16, 2667–2687 (2021).
MedlineGoogle Scholar
56. Parmar JJ, Singh DJ, Hegde DD et al. Development and evaluation of inhalational liposomal system of budesonide for better management of asthma. Indian J. Pharm. Sci. 72(4), 442–448 (2010).
Medline CASGoogle Scholar
57. Al-Amin MD, Bellato F, Mastrotto F et al. Dexamethasone loaded liposomes by thin-film hydration and microfluidic procedures: formulation challenges. Int. J. Mol. Sci. 21(5), E1611 (2020).
Medline CASGoogle Scholar
58. Bourganis V, Kammona O, Alexopoulos A, Kiparissides C. Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics. Eur. J. Pharm. Biopharm. 128, 337–362 (2018).
Medline CASGoogle Scholar
59. Khosa A, Reddi S, Saha RN. Nanostructured lipid carriers for site-specific drug delivery. Biomed. Pharmacother. Biomed. Pharmacother. 103, 598–613 (2018).
Medline CASGoogle Scholar
60. Tapeinos C, Battaglini M, Ciofani G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J. Control. Rel. Off. J. Control. Rel. Soc. 264, 306–332 (2017).
Medline CASGoogle Scholar
61. Desoqi MH, El-Sawy HS, Kafagy E, Ghorab M, Gad S. Fluticasone propionate-loaded solid lipid nanoparticles with augmented anti-inflammatory activity: optimisation, characterisation and pharmacodynamic evaluation on rats. J. Microencapsul. 38(3), 177–191 (2021).
Medline CASGoogle Scholar
62. Beloqui A, Coco R, Alhouayek M et al. Budesonide-loaded nanostructured lipid carriers reduce inflammation in murine DSS-induced colitis. Int. J. Pharm. 454(2), 775–783 (2013).
Medline CASGoogle Scholar
63. Esmaeili M, Aghajani M, Abbasalipourkabir R, Amani A. Budesonide-loaded solid lipid nanoparticles for pulmonary delivery: preparation, optimization, and aerodynamic behavior. Artif. Cells Nanomed. Biotechnol. 44(8), 1964–1971 (2016).
Medline CASGoogle Scholar
64. Khan I, Hussein S, Houacine C et al. Fabrication, characterization and optimization of nanostructured lipid carrier formulations using Beclomethasone dipropionate for pulmonary drug delivery via medical nebulizers. Int. J. Pharm. 598, 120376 (2021).
Medline CASGoogle Scholar
65. Jain K, Jain NK. Surface engineered dendrimers as antiangiogenic agent and carrier for anticancer drug: dual attack on cancer. J. Nanosci. Nanotechnol. 14(7), 5075–5087 (2014).
Medline CASGoogle Scholar
66. Xu Y, Liu H, Song L. Novel drug delivery systems targeting oxidative stress in chronic obstructive pulmonary disease: a review. J. Nanobiotechnol. 18(1), 145 (2020).
Medline CASGoogle Scholar
67. Ryan GM, Kaminskas LM, Kelly BD, Owen DJ, McIntosh MP, Porter CJH. Pulmonary administration of PEGylated polylysine dendrimers: absorption from the lung versus retention within the lung is highly size-dependent. Mol. Pharm. 10(8), 2986–2995 (2013).
Medline CASGoogle Scholar
68. Zhong Q, Merkel OM, Reineke JJ, da Rocha SRP. Effect of the route of administration and PEGylation of poly(amidoamine) dendrimers on their systemic and lung cellular biodistribution. Mol. Pharm. 13(6), 1866–1878 (2016).
Medline CASGoogle Scholar
69. Nasr M, Najlah M, D'Emanuele A, Elhissi A. PAMAM dendrimers as aerosol drug nanocarriers for pulmonary delivery via nebulization. Int. J. Pharm. 461(1–2), 242–250 (2014).
Medline CASGoogle Scholar
70. Kim S, Park H, Song Y et al. Reduction of oxidative stress by p-hydroxybenzyl alcohol-containing biodegradable polyoxalate nanoparticulate antioxidant. Biomaterials 32(11), 3021–3029 (2011).
Medline CASGoogle Scholar
71. Madl AK, Plummer LE, Carosino C, Pinkerton KE. Nanoparticles, lung injury, and the role of oxidant stress. Annu. Rev. Physiol. 76, 447–465 (2014).
Medline CASGoogle Scholar
72. Beck-Broichsitter M, Gauss J, Gessler T, Seeger W, Kissel T, Schmehl T. Pulmonary targeting with biodegradable salbutamol-loaded nanoparticles. J. Aerosol Med. Pulm. Drug Deliv. 23(1), 47–57 (2010).
Medline CASGoogle Scholar
73. Mohamed A, Pekoz AY, Ross K, Hutcheon GA, Saleem IY. Pulmonary delivery of nanocomposite microparticles (NCMPs) incorporating miR-146a for treatment of COPD. Int. J. Pharm. 569, 118524 (2019).
Medline CASGoogle Scholar
74. Virmani R, Pathak K. Targeted polymeric micellar systems for respiratory diseases [Internet]. In: Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems, Elsevier, 411–439 (2020).
Google Scholar
75. Gaber NN, Darwis Y, Peh K-K, Tan YT-F. Characterization of polymeric micelles for pulmonary delivery of beclomethasone dipropionate. J. Nanosci. Nanotechnol. 6(9), 3095–3101 (2006).
Medline CASGoogle Scholar
76. Pellosi DS, d'Angelo I, Maiolino S et al. In vitro/in vivo investigation on the potential of Pluronic^® mixed micelles for pulmonary drug delivery. Eur. J. Pharm. Biopharm. 130, 30–38 (2018).
Medline CASGoogle Scholar
77. Sahib MN, Darwis Y, Peh KK, Abdulameer SA, Tan YTF. Rehydrated sterically stabilized phospholipid nanomicelles of budesonide for nebulization: physicochemical characterization and in vitro, in vivo evaluations. Int. J. Nanomed. 6, 2351–2366 (2011).
Medline CASGoogle Scholar
78. Craparo EF, Teresi G, Bondi’ ML, Licciardi M, Cavallaro G. Phospholipid-polyaspartamide micelles for pulmonary delivery of corticosteroids. Int. J. Pharm. 406(1–2), 135–144 (2011).
Medline CASGoogle Scholar
79. Yoncheva K, Petrov P, Pencheva I, Konstantinov S. Triblock polymeric micelles as carriers for anti-inflammatory drug delivery. J. Microencapsul. 32(3), 224–230 (2015).
Medline CASGoogle Scholar
80. Bhardwaj P, Tripathi P, Gupta R, Pandey S. Niosomes: a review on niosomal research in the last decade. J. Drug Deliv. Sci. Technol. 56, 101581 (2020).
CASGoogle Scholar
81. Terzano C, Allegra L, Alhaique F, Marianecci C, Carafa M. Non-phospholipid vesicles for pulmonary glucocorticoid delivery. Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft Pharm. Verfahrenstechnik EV. 59(1), 57–62 (2005).
Medline CASGoogle Scholar
82. Nasr M, Nawaz S, Elhissi A. Amphotericin B lipid nanoemulsion aerosols for targeting peripheral respiratory airways via nebulization. Int. J. Pharm. 436(1–2), 611–616 (2012).
Medline CASGoogle Scholar
83. Singh S, Virmani T, Kohli K. Nanoemulsion system for improvement of raspberry ketone oral bioavailability. Indo Glob. J. Pharm. Sci. 10(01), 33–42 (2020).
Google Scholar
84. Amani A, York P, Chrystyn H, Clark BJ. Evaluation of a nanoemulsion-based formulation for respiratory delivery of budesonide by nebulizers. AAPS PharmSciTech. 11(3), 1147–1151 (2010).
Medline CASGoogle Scholar
85. De Leo V, Ruscigno S, Trapani A et al. Preparation of drug-loaded small unilamellar liposomes and evaluation of their potential for the treatment of chronic respiratory diseases. Int. J. Pharm. 545(1–2), 378–388 (2018).
MedlineGoogle Scholar
86. Nirale NM, Vidhate RD, Nagarsenker MS. Fluticasone propionate liposomes for pulmonary delivery. Indian J. Pharm. Sci. 71(6), 709–711 (2009).
Google Scholar
87. Aljihani SA, Alehaideb Z, Alarfaj RE et al. Enhancing azithromycin antibacterial activity by encapsulation in liposomes/liposomal-N-acetylcysteine formulations against resistant clinical strains of Escherichia coli. Saudi J. Biol. Sci. 27(11), 3065–3071 (2020).
Medline CASGoogle Scholar
88. Kanhai KMS, Zuiker RGJA, Stavrakaki I et al. Glutathione-PEGylated liposomal methylprednisolone in comparison to free methylprednisolone: slow release characteristics and prolonged lymphocyte depression in a first-in-human study. Br. J. Clin. Pharmacol. 84(5), 1020–1028 (2018).
Medline CASGoogle Scholar
89. Amasya G, Şengel Türk CT, Badilli U, Tarimci N. Development and statistical optimization of solid lipid nanoparticle formulations of fluticasone propionate. Turk. J. Pharm. Sci. 17(4), 359–366 (2020).
Medline CASGoogle Scholar
90. Doktorovová S, Araújo J, Garcia ML, Rakovský E, Souto EB. Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC). Colloids Surf. B Biointerfaces. 75(2), 538–542 (2010).
Medline CASGoogle Scholar
91. Jaafar-Maalej C, Andrieu V, Elaissari A, Fessi H. Beclomethasone-loaded lipidic nanocarriers for pulmonary drug delivery: preparation, characterization and in vitro drug release. J. Nanosci. Nanotechnol. 11(3), 1841–1851 (2011).
Medline CASGoogle Scholar
92. Daman Z, Gilani K, Rouholamini Najafabadi A, Eftekhari HR, Barghi MA. Formulation of inhalable lipid-based salbutamol sulfate microparticles by spray drying technique. DARU J. Pharm. Sci. 22(1), 50 (2014).
Google Scholar
93. Amore E, Manca ML, Ferraro M et al. Salmeterol Xinafoate (SX) loaded into mucoadhesive solid lipid microparticles for COPD treatment. Int. J. Pharm. 562, 351–358 (2019).
Medline CASGoogle Scholar
94. Amore E, Ferraro M, Manca ML et al. Mucoadhesive solid lipid microparticles for controlled release of a corticosteroid in the chronic obstructive pulmonary disease treatment. Nanomed. 12(19), 2287–2302 (2017).
CASGoogle Scholar
95. Nance E, Kambhampati SP, Smith ES et al. Dendrimer-mediated delivery of N-acetyl cysteine to microglia in a mouse model of Rett syndrome. J. Neuroinflamm. 14, 252 (2017).
MedlineGoogle Scholar
96. Conti DS, Brewer D, Grashik J, Avasarala S, da Rocha SRP. Poly(amidoamine) dendrimer nanocarriers and their aerosol formulations for siRNA delivery to the lung epithelium. Mol. Pharm. 11(6), 1808–1822 (2014).
Medline CASGoogle Scholar
97. Falconieri M, Adamo M, Monasterolo C, Bergonzi M, Coronnello M, Bilia A. New dendrimer-based nanoparticles enhance curcumin solubility. Planta Med. 83(05), 420–425 (2016).
MedlineGoogle Scholar
98. Ali H, Weigmann B, Collnot E-M, Khan SA, Windbergs M, Lehr C-M. Budesonide loaded PLGA nanoparticles for targeting the inflamed intestinal mucosa–pharmaceutical characterization and fluorescence imaging. Pharm. Res. 33(5), 1085–1092 (2016).
Medline CASGoogle Scholar
99. Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int. J. Pharm. 392(1–2), 1–19 (2010).
Medline CASGoogle Scholar
100. Hidalgo A, Cruz A, Pérez-Gil J. Pulmonary surfactant and nanocarriers: toxicity versus combined nanomedical applications. Biochim. Biophys. Acta BBA - Biomembr. 1859(9), 1740–1748 (2017).
Medline CASGoogle Scholar
101. Song S, Embury J, Laipis PJ, Berns KI, Crawford JM, Flotte TR. Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors. Gene Ther. 8(17), 1299–1306 (2001).
Medline CASGoogle Scholar
102. Metz R, DiCola M, Kurihara T et al. Mode of action of RNA/DNA oligonucleotides. Chest 121(3), 91S–97S (2002).
Medline CASGoogle Scholar
103. Chen Y-T, Miao K, Zhou L, Xiong W-N. Stem cell therapy for chronic obstructive pulmonary disease. Chin. Med. J. (Engl.). 134(13), 1535–1545 (2021).
Medline CASGoogle Scholar
104. Sankar V. Proniosomes as carrier for the sustained delivery of salbutamol. Indian Drugs 48(8), 22–32 (2011).
Google Scholar
105. Calvert BA, Ryan Firth AL. Application of iPSC to modelling of respiratory diseases. Adv. Exp. Med. Biol. 1237, 1–16 (2020).
Medline CASGoogle Scholar
106. Toraldo DM, Toraldo S, Conte L. The clinical use of stem cell research in chronic obstructive pulmonary disease: a critical analysis of current policies. J. Clin. Med. Res. 10(9), 671–678 (2018).
Medline CASGoogle Scholar
107. Laffey JG, Kavanagh BP. Negative trials in critical care: why most research is probably wrong. Lancet Respir. Med. 6(9), 659–660 (2018).
MedlineGoogle Scholar
108. Midori Okabe MD. Beyond the limitation of randomized controlled trials (RCTs)-current drug repositioning by using human induced pluripotent stem (iPS) cells technology- [Internet]. Scientific Communication and Education. http://biorxiv.org/lookup/doi/10.1101/111435
Google Scholar
109. Sui B-D, Zheng C-X, Li M, Jin Y, Hu C-H. Epigenetic regulation of mesenchymal stem cell homeostasis. Trends Cell Biol. 30(2), 97–116 (2020).
Medline CASGoogle Scholar
110. Liu A, Liu L, Chen S et al. Activation of canonical wnt pathway promotes differentiation of mouse bone marrow-derived MSCs into type II alveolar epithelial cells, confers resistance to oxidative stress, and promotes their migration to injured lung tissue in vitro. J. Cell. Physiol. 228(6), 1270–1283 (2013).
Medline CASGoogle Scholar
111. Muralidharan P, Hayes D, Mansour HM. Dry powder inhalers in COPD, lung inflammation and pulmonary infections. Expert Opin. Drug Deliv. 12(6), 947–962 (2015).
Medline CASGoogle Scholar
112. Willis L, Hayes D, Mansour HM. Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery. Lung 190(3), 251–262 (2012).
Medline CASGoogle Scholar

Vol. 17, No. 24

Metrics

Downloaded 2,091 times

History

Received 29 October 2021

Accepted 6 June 2022

Published online 20 July 2022

Published in print October 2022

Information

Keywords

Acknowledgments

The authors acknowledge the support of MVN University, Palwal and Uttar Pradesh University of Medical Sciences, Saifai, Etawah.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download

Nanocarrier-based approaches to combat chronic obstructive pulmonary disease

Abstract

References